DeepMed Research

Incyte

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 2.5K

Market Cap: $12.6B

Website

Introduction: Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

Phase 2

Completed

Conditions: Vitiligo

Interventions: Drug: Ruxolitinib 1.5% cream
Device: NB-UVB phototherapy

First Posted Date: 2022-02-21

Last Posted Date: 2025-02-20

Lead Sponsor: Incyte Corporation

Target Recruit Count: 55

Registration Number: NCT05247489

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
First Oc Dermatology, Fountain Valley, California, United States
🇺🇸
Principle Research Solutions, Spokane, Washington, United States

and more 10 locations

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: INCB0123667
Drug: Bevacizumab
Drug: Olaparib
Drug: Paclitaxel
Drug: Palbociclib
Drug: Ribociclib
Drug: Fulvestrant

First Posted Date: 2022-02-14

Last Posted Date: 2025-03-25

Lead Sponsor: Incyte Corporation

Target Recruit Count: 604

Registration Number: NCT05238922

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope-Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States

and more 40 locations

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

Phase 3

Withdrawn

Conditions: Chronic Hand Eczema (CHE)

Interventions: Drug: Vehicle
Drug: Ruxolitinib cream

First Posted Date: 2022-02-10

Last Posted Date: 2022-11-10

Lead Sponsor: Incyte Corporation

Registration Number: NCT05233410

Locations: 🇵🇱
Etg Warszawa, Warsaw, Poland
🇩🇪
Universitaetsklinikum Schleswig Holstein - Campus Luebeck, Luebeck, Germany
🇩🇪
Gemeinschaftspraxis, Mahlow, Germany

and more 35 locations

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

Phase 1

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2022-02-03

Last Posted Date: 2025-02-14

Lead Sponsor: Incyte Corporation

Target Recruit Count: 53

Registration Number: NCT05222555

Locations: 🇨🇿
Vseobecna Fakultni Nemocnice V Praze, Praha, Czechia
🇨🇿
Fakultni nemocnice v Motole, Praha, Czechia
🇨🇿
Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia

and more 59 locations

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

Phase 3

Withdrawn

Conditions: Hand Eczema

Interventions: Drug: Ruxolitinib cream
Drug: Vehicle

First Posted Date: 2022-02-02

Last Posted Date: 2022-11-17

Lead Sponsor: Incyte Corporation

Registration Number: NCT05219864

Locations: 🇺🇸
Raoof Md Encino, Encino, California, United States
🇺🇸
Southwest Skin Specialists Phoenix Biltmore, Phoenix, Arizona, United States
🇺🇸
First Oc Dermatology, Fountain Valley, California, United States

and more 45 locations

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Ruxolitinib cream
Drug: Vehicle

First Posted Date: 2021-11-19

Last Posted Date: 2024-08-15

Lead Sponsor: Incyte Corporation

Target Recruit Count: 77

Registration Number: NCT05127421

Locations: 🇺🇸
Science37, Culver City, California, United States

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: INCB086550

First Posted Date: 2021-11-01

Last Posted Date: 2022-06-21

Lead Sponsor: Incyte Corporation

Target Recruit Count: 7

Registration Number: NCT05101369

Locations: 🇬🇧
Covance Leeds Cru, Leeds, United Kingdom

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

Phase 1

Completed

Conditions: Renal Impairment
Hemodialysis

Interventions: Drug: INCB000928

First Posted Date: 2021-10-29

Last Posted Date: 2023-05-15

Lead Sponsor: Incyte Corporation

Target Recruit Count: 48

Registration Number: NCT05099445

Locations: 🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸
Nucleus Network Minneapolis Clinic, Saint Paul, Minnesota, United States
🇺🇸
Clinical Pharmacology of Miami, Hialeah, Florida, United States

and more 2 locations

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Phase 2

Recruiting

Conditions: Fibrodysplasia Ossificans Progressiva (FOP)

Interventions: Drug: INCB000928
Drug: Placebo

First Posted Date: 2021-10-25

Last Posted Date: 2025-04-02

Lead Sponsor: Incyte Corporation

Target Recruit Count: 98

Registration Number: NCT05090891

Locations: 🇨🇳
Beijing Childrens Hospital Capital Medical University, Beijing, China
🇨🇳
Tongji Hospital of Tongji University, Shanghai, China
🇨🇳
Shanghai Childrens Medical Center, Shanghai, China

and more 26 locations

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

Phase 3

Terminated

Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)

Interventions: Drug: parsaclisinib
Drug: placebo

First Posted Date: 2021-10-11

Last Posted Date: 2025-01-15

Lead Sponsor: Incyte Corporation

Target Recruit Count: 13

Registration Number: NCT05073458

Locations: 🇵🇱
Investigative Site PL001, Legnica, Poland
🇵🇱
Investigative Site PL005, Opole, Poland
🇦🇹
Investigative Site AT002, Salzburg CET, Austria

and more 53 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy